PALO ALTO, Calif., July 3, 2025 /PRNewswire/ -- Recently, the prestigious media platform Caijing Magazine officially unveiled its "Top 50 Global Chinese Venture Capitalists" list....
VANCOUVER, British Columbia, July 02, 2025 (GLOBE NEWSWIRE) -- DMG Blockchain Solutions Inc. (TSX-V: DMGI) (OTCQB: DMGGF) (FRANKFURT: 6AX) ("DMG" or the "Company"), a vertically integrated blockchain and data center technology company, today announces its preliminary operational results for June 2025:
BANGKOK, July 3, 2025 /PRNewswire/ -- J&V Energy Technology (6869-TW), a leader in integrated sustainable development and circular economy solutions in Taiwan, has earned global recognition for...
TOKYO, July 3, 2025 /PRNewswire/ -- The Australian Securities Exchange (ASX), the Tokyo Stock Exchange, Inc. (TSE), and Fujitsu Limited on June 2, 2025 signed...
SUNNYVALE, Calif., July 2, 2025 /PRNewswire/ -- Today, Synopsys, Inc. (Nasdaq: SNPS) issued the below statement in connection with the lifting of recent U.S. export...
VANCOUVER, British Columbia, July 02, 2025 (GLOBE NEWSWIRE) -- Commodities & Resources PTE Ltd. (the “Acquiror"), a private investment company incorporated in Singapore, announces that on April 8, 2025, the Acquiror acquired Common Shares of Belmont Resources Inc. (TSX-V: BEA)(the “Issuer”). The Issuer completed a private placement of Common Shares, issuing a total of 4,000,000 shares to the Acquiror at a price of $0.045 per share for proceeds of $180,000 (the “Private Placement”).
INDIANAPOLIS and DENVER, July 2, 2025 /PRNewswire/ -- After 4 years in development, Lore Link is now publicly available as an online management tool...
ZEGFROVY is the only approved targeted oral treatment for NSCLC with EGFR exon20insApproval follows the U.S. FDA's Priority Review and is supported by the pivotal WU-KONG1 Part B study, in which...
SHANGHAI, July 3, 2025 /PRNewswire/ -- USI, Universal Scientific Industrial (Shanghai) Co., Ltd., a global leader in electronic design and manufacturing services, announced the successful...
BOSTON, July 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on July 1, 2025, the Compensation Committee of Praxis’ Board of Directors granted restricted stock unit awards covering an aggregate of 2,100 shares of its common stock to three new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees’ entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).